AFFIMED N.V. news, videos and press releases - Page 3
For more news please use our advanced search feature.
AFFIMED N.V. - More news...
AFFIMED N.V. - More news...
- Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
- Affimed Reports 2022 Financial Results and Operational Progress
- Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
- Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
- AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
- Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
- AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
- Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
- Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
- Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
- Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting
- Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
- Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
- Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
- Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress
- Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
- Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
- Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
- Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting
- Affimed to Present at the 2022 Jefferies London Healthcare Conference
- Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
- Affimed to Present at Upcoming Investor Conferences
- Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
- Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
- Affimed Establishes Scientific Advisory Board
- Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
- Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
- Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
- Affimed to Present at the 2022 Jefferies Healthcare Conference
